JP2019532078A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532078A5 JP2019532078A5 JP2019520736A JP2019520736A JP2019532078A5 JP 2019532078 A5 JP2019532078 A5 JP 2019532078A5 JP 2019520736 A JP2019520736 A JP 2019520736A JP 2019520736 A JP2019520736 A JP 2019520736A JP 2019532078 A5 JP2019532078 A5 JP 2019532078A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- unsubstituted
- substituted
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 329
- 229910052739 hydrogen Inorganic materials 0.000 claims description 213
- 239000001257 hydrogen Substances 0.000 claims description 213
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 118
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 96
- 208000035475 disorder Diseases 0.000 claims description 90
- 150000002431 hydrogen Chemical class 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 76
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
- 150000001721 carbon Chemical group 0.000 claims description 38
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 230000002496 gastric effect Effects 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 21
- 125000001475 halogen functional group Chemical group 0.000 claims description 21
- 125000004043 oxo group Chemical group O=* 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 18
- 229930182558 Sterol Natural products 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 235000003702 sterols Nutrition 0.000 claims description 17
- 238000003786 synthesis reaction Methods 0.000 claims description 17
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 16
- 208000028017 Psychotic disease Diseases 0.000 claims description 16
- 210000003169 central nervous system Anatomy 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 13
- 150000003432 sterols Chemical class 0.000 claims description 12
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 11
- 208000011231 Crohn disease Diseases 0.000 claims description 11
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 11
- 208000012826 adjustment disease Diseases 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 208000016285 Movement disease Diseases 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 208000022821 personality disease Diseases 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 208000016583 Anus disease Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 208000019022 Mood disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 208000009205 Tinnitus Diseases 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 208000029560 autism spectrum disease Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000001314 paroxysmal effect Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 208000014644 Brain disease Diseases 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010047571 Visual impairment Diseases 0.000 claims description 4
- 208000029257 vision disease Diseases 0.000 claims description 4
- 230000004393 visual impairment Effects 0.000 claims description 4
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000018460 Feeding disease Diseases 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000022131 polyp of large intestine Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 59
- 125000005843 halogen group Chemical group 0.000 description 20
- 208000014617 hemorrhoid Diseases 0.000 description 14
- 206010015037 epilepsy Diseases 0.000 description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 description 10
- 208000000094 Chronic Pain Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 208000005298 acute pain Diseases 0.000 description 6
- 206010048946 Anal abscess Diseases 0.000 description 5
- 208000008958 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Diseases 0.000 description 5
- 208000020925 Bipolar disease Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 208000030814 Eating disease Diseases 0.000 description 5
- 206010072378 Encephalitis autoimmune Diseases 0.000 description 5
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 5
- 208000034693 Laceration Diseases 0.000 description 5
- 208000032580 NMDA receptor encephalitis Diseases 0.000 description 5
- 201000009916 Postpartum depression Diseases 0.000 description 5
- 208000004680 Rectal Fistula Diseases 0.000 description 5
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 5
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 206010041247 Social fear Diseases 0.000 description 5
- 206010002156 anal fistula Diseases 0.000 description 5
- 208000029188 anti-NMDA receptor encephalitis Diseases 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 235000014632 disordered eating Nutrition 0.000 description 5
- 208000016354 hearing loss disease Diseases 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 208000014081 polyp of colon Diseases 0.000 description 5
- 208000028173 post-traumatic stress disease Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 125000002328 sterol group Chemical group 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 208000024581 Compulsive Personality disease Diseases 0.000 description 4
- 208000007386 hepatic encephalopathy Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 241000004297 Draba Species 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000007772 internal hemorrhoid Diseases 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022039315A JP2022069555A (ja) | 2016-10-18 | 2022-03-14 | オキシステロールおよびその使用方法 |
| JP2024009591A JP2024028631A (ja) | 2016-10-18 | 2024-01-25 | オキシステロールおよびその使用方法 |
| JP2025097029A JP2025123284A (ja) | 2016-10-18 | 2025-06-10 | オキシステロールおよびその使用方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409767P | 2016-10-18 | 2016-10-18 | |
| US201662409761P | 2016-10-18 | 2016-10-18 | |
| US201662409774P | 2016-10-18 | 2016-10-18 | |
| US201662409764P | 2016-10-18 | 2016-10-18 | |
| US201662409772P | 2016-10-18 | 2016-10-18 | |
| US62/409,761 | 2016-10-18 | ||
| US62/409,767 | 2016-10-18 | ||
| US62/409,772 | 2016-10-18 | ||
| US62/409,774 | 2016-10-18 | ||
| US62/409,764 | 2016-10-18 | ||
| PCT/US2017/057277 WO2018075699A1 (en) | 2016-10-18 | 2017-10-18 | Oxysterols and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039315A Division JP2022069555A (ja) | 2016-10-18 | 2022-03-14 | オキシステロールおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532078A JP2019532078A (ja) | 2019-11-07 |
| JP2019532078A5 true JP2019532078A5 (enExample) | 2020-11-26 |
| JP7118957B2 JP7118957B2 (ja) | 2022-08-16 |
Family
ID=60263023
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520736A Active JP7118957B2 (ja) | 2016-10-18 | 2017-10-18 | オキシステロールおよびその使用方法 |
| JP2022039315A Withdrawn JP2022069555A (ja) | 2016-10-18 | 2022-03-14 | オキシステロールおよびその使用方法 |
| JP2024009591A Pending JP2024028631A (ja) | 2016-10-18 | 2024-01-25 | オキシステロールおよびその使用方法 |
| JP2025097029A Pending JP2025123284A (ja) | 2016-10-18 | 2025-06-10 | オキシステロールおよびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022039315A Withdrawn JP2022069555A (ja) | 2016-10-18 | 2022-03-14 | オキシステロールおよびその使用方法 |
| JP2024009591A Pending JP2024028631A (ja) | 2016-10-18 | 2024-01-25 | オキシステロールおよびその使用方法 |
| JP2025097029A Pending JP2025123284A (ja) | 2016-10-18 | 2025-06-10 | オキシステロールおよびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11149054B2 (enExample) |
| EP (2) | EP3529257B1 (enExample) |
| JP (4) | JP7118957B2 (enExample) |
| KR (2) | KR20230142639A (enExample) |
| CN (4) | CN119350419A (enExample) |
| AU (3) | AU2017345400B2 (enExample) |
| BR (1) | BR112019008032A2 (enExample) |
| CA (2) | CA3041088C (enExample) |
| DK (1) | DK3529257T3 (enExample) |
| ES (1) | ES2952106T3 (enExample) |
| IL (2) | IL297804A (enExample) |
| MA (1) | MA46566A (enExample) |
| MX (4) | MX2019004578A (enExample) |
| RU (1) | RU2019115113A (enExample) |
| TW (3) | TW202444381A (enExample) |
| WO (1) | WO2018075699A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| ES2699445T3 (es) | 2013-03-13 | 2019-02-11 | Sage Therapeutics Inc | Esteroides neuroactivos y métodos de utilización de los mismos |
| EP3157528B1 (en) | 2014-06-18 | 2023-09-13 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| KR20240137111A (ko) | 2015-07-06 | 2024-09-19 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| CA3019146C (en) * | 2016-04-01 | 2024-03-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| LT3481846T (lt) | 2016-07-07 | 2021-08-25 | Sage Therapeutics, Inc. | 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles |
| WO2018064649A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| MX2019004578A (es) | 2016-10-18 | 2019-10-09 | Sage Therapeutics Inc | Oxisteroles y metodos de uso de los mismos. |
| MA46565A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| WO2020260558A1 (en) | 2019-06-27 | 2020-12-30 | Phenex Pharmaceuticals Ag | 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases |
| GB201913752D0 (en) | 2019-09-24 | 2019-11-06 | Syngenta Crop Protection Ag | Herbicidal compounds |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| GB201914277D0 (en) | 2019-10-03 | 2019-11-20 | Syngenta Crop Protection Ag | Herbicidal compounds |
| GB201917898D0 (en) | 2019-12-06 | 2020-01-22 | Syngenta Crop Protection Ag | Herbicidal compounds |
| EP4171504A4 (en) * | 2020-06-26 | 2024-07-10 | Durect Corporation | USE OF OXYGENATED CHOLESTEROL SULFATES FOR THE TREATMENT OF AUTOIMMUNE CONDITIONS |
| US20250319105A1 (en) | 2021-06-11 | 2025-10-16 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| EP4405370A1 (en) | 2021-09-22 | 2024-07-31 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| US20250387409A1 (en) * | 2021-11-10 | 2025-12-25 | Umecrine Cognition Ab | 3-beta-hydroxy-3-alpha-ethyl steroids for modulation of the alpha-3 subtype of the gabaa receptor |
| WO2023083343A1 (en) | 2021-11-15 | 2023-05-19 | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | Polycyclic compounds and methods thereof |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN116143859A (zh) * | 2022-12-09 | 2023-05-23 | 江苏佳尔科药业集团股份有限公司 | 5α-孕甾-3,20-二酮的制备方法 |
| WO2025221731A1 (en) * | 2024-04-15 | 2025-10-23 | Sage Therapeutics, Inc. | Nmda receptor-modulating compounds and methods of use thereof |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5382766U (enExample) | 1976-12-11 | 1978-07-08 | ||
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| JPS5758506Y2 (enExample) | 1978-05-09 | 1982-12-14 | ||
| JPS54156176A (en) | 1978-05-30 | 1979-12-08 | Matsushita Electric Industrial Co Ltd | Method of producing circuit pattern punched die for printed circuit |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| JPS62187485U (enExample) | 1986-05-15 | 1987-11-28 | ||
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE69518509T2 (de) | 1994-02-14 | 2001-04-19 | Euro-Celtique S.A., Luxemburg/Luxembourg | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| WO1996016076A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| CZ394197A3 (cs) | 1995-06-06 | 1998-06-17 | Cocensys, Inc. | Neuroaktivní steroidy androstanové a pregnanové řady |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| DE69630802T2 (de) | 1995-06-23 | 2004-08-12 | Novo Nordisk A/S | Meiose regulierende verbindungen. |
| EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| AU3595799A (en) | 1998-05-11 | 1999-11-29 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| ATE375994T1 (de) | 2001-05-03 | 2007-11-15 | Univ Chicago | Leber x rezeptoragonisten |
| TW200300078A (en) | 2001-11-08 | 2003-05-16 | Univ Chicago | Method of treating disorder related to high cholesterol concentration |
| CA2468989A1 (en) | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
| PE20040306A1 (es) | 2002-03-27 | 2004-05-29 | Phytopharm Plc | Metodos terapeuticos de sapogeninas y sus derivados |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| JP2004012949A (ja) | 2002-06-10 | 2004-01-15 | Canon Inc | 電気泳動表示装置 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| EP1814558B1 (en) | 2004-11-01 | 2010-12-15 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| MX2009005335A (es) | 2006-11-21 | 2009-06-08 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. |
| ES2400026T3 (es) | 2007-06-20 | 2013-04-05 | Auspex Pharmaceuticals, Inc. | N-arilpiridinonas sustituidas como inhibidores fibróticos |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059961A2 (en) | 2007-11-06 | 2009-05-14 | N.V. Organon | A method of hormone suppression in humans |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| SG195568A1 (en) | 2008-05-09 | 2013-12-30 | Univ Emory | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2011014661A2 (en) | 2009-07-29 | 2011-02-03 | The University Of Chicago | Liver x receptor agonists |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| GB2467232B (en) * | 2010-01-25 | 2011-02-23 | Crane Electronics | Variable torque-rate test joint |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| WO2013163455A2 (en) | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | A drug screening platform for rett syndrome |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| WO2014028942A2 (en) | 2012-08-17 | 2014-02-20 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| HRP20181048T1 (hr) | 2012-12-18 | 2018-08-24 | Washington University | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja |
| CN112552364A (zh) | 2013-01-23 | 2021-03-26 | 司菲埃拉制药私人有限公司 | 用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物 |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| RU2015143463A (ru) * | 2013-03-13 | 2017-04-19 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их применение |
| ES2699445T3 (es) | 2013-03-13 | 2019-02-11 | Sage Therapeutics Inc | Esteroides neuroactivos y métodos de utilización de los mismos |
| CN105744937A (zh) | 2013-09-25 | 2016-07-06 | 范安德尔研究所 | 高效糖皮质激素 |
| EP3157528B1 (en) | 2014-06-18 | 2023-09-13 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2016007762A1 (en) | 2014-07-09 | 2016-01-14 | Duke University | Compositions and methods for the repair of myelin |
| MY202135A (en) | 2014-10-07 | 2024-04-05 | Sage Therapeutics Inc | Uses of neuroactive compounds |
| HK1255500A1 (zh) | 2015-07-06 | 2019-08-16 | Sage Therapeutics, Inc. | 氧固醇及其使用方法 |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| KR20240137111A (ko) | 2015-07-06 | 2024-09-19 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| CA3019146C (en) | 2016-04-01 | 2024-03-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| LT3481846T (lt) | 2016-07-07 | 2021-08-25 | Sage Therapeutics, Inc. | 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| WO2018064649A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| MX2019004578A (es) | 2016-10-18 | 2019-10-09 | Sage Therapeutics Inc | Oxisteroles y metodos de uso de los mismos. |
| MA46565A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| US11066437B2 (en) | 2017-06-23 | 2021-07-20 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of bile acid derivatives |
| EP3706755A4 (en) | 2017-11-10 | 2021-11-10 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN THE TREATMENT OF GENETIC EPILEPTIC DISORDERS |
-
2017
- 2017-10-18 MX MX2019004578A patent/MX2019004578A/es unknown
- 2017-10-18 CA CA3041088A patent/CA3041088C/en active Active
- 2017-10-18 CN CN202411361474.9A patent/CN119350419A/zh active Pending
- 2017-10-18 RU RU2019115113A patent/RU2019115113A/ru unknown
- 2017-10-18 CN CN202210676312.9A patent/CN115181153A/zh active Pending
- 2017-10-18 IL IL297804A patent/IL297804A/en unknown
- 2017-10-18 CN CN201780077719.7A patent/CN110267966B/zh active Active
- 2017-10-18 CN CN202210185374.XA patent/CN114478677B/zh active Active
- 2017-10-18 AU AU2017345400A patent/AU2017345400B2/en active Active
- 2017-10-18 BR BR112019008032-5A patent/BR112019008032A2/pt active Search and Examination
- 2017-10-18 TW TW113112851A patent/TW202444381A/zh unknown
- 2017-10-18 MA MA046566A patent/MA46566A/fr unknown
- 2017-10-18 TW TW111135365A patent/TWI892042B/zh active
- 2017-10-18 EP EP17794489.9A patent/EP3529257B1/en active Active
- 2017-10-18 ES ES17794489T patent/ES2952106T3/es active Active
- 2017-10-18 TW TW106135757A patent/TWI815800B/zh active
- 2017-10-18 EP EP23171489.0A patent/EP4252848A3/en active Pending
- 2017-10-18 KR KR1020237032535A patent/KR20230142639A/ko not_active Ceased
- 2017-10-18 DK DK17794489.9T patent/DK3529257T3/da active
- 2017-10-18 JP JP2019520736A patent/JP7118957B2/ja active Active
- 2017-10-18 US US16/343,235 patent/US11149054B2/en active Active
- 2017-10-18 CA CA3234484A patent/CA3234484A1/en active Pending
- 2017-10-18 KR KR1020197014199A patent/KR102583278B1/ko active Active
- 2017-10-18 WO PCT/US2017/057277 patent/WO2018075699A1/en not_active Ceased
- 2017-10-18 IL IL266093A patent/IL266093B2/en unknown
-
2019
- 2019-04-17 MX MX2022012317A patent/MX2022012317A/es unknown
- 2019-04-17 MX MX2021013075A patent/MX2021013075A/es unknown
- 2019-04-17 MX MX2022012313A patent/MX2022012313A/es unknown
-
2021
- 2021-08-05 US US17/395,155 patent/US11851457B2/en active Active
-
2022
- 2022-02-10 AU AU2022200884A patent/AU2022200884B2/en active Active
- 2022-03-14 JP JP2022039315A patent/JP2022069555A/ja not_active Withdrawn
-
2023
- 2023-11-09 US US18/388,390 patent/US20240199682A1/en active Pending
-
2024
- 2024-01-25 JP JP2024009591A patent/JP2024028631A/ja active Pending
- 2024-04-29 AU AU2024202774A patent/AU2024202774A1/en active Pending
-
2025
- 2025-06-10 JP JP2025097029A patent/JP2025123284A/ja active Pending